Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the fourth episode of its NETHERTON NOW video series, featuring Mandy Aldwin-Easton, a prominent patient advocate and leader in rare disease advocacy organizations. The episode highlights the devastating impact of Netherton Syndrome, a rare skin condition characterized by severe pain, chronic flare-ups, and frequent hospitalizations.
Mandy, who serves as Medical and Communications Manager of the UK-based Ichthyosis Support Group and President of the European Network for Ichthyosis, shares her personal journey with the condition. The release coincides with Quoin's advancement of QRX003, their lead product candidate for Netherton Syndrome treatment, which has shown promising results in ongoing pivotal clinical trials.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha pubblicato il quarto episodio della serie video NETHERTON NOW, con Mandy Aldwin-Easton, nota rappresentante dei pazienti e figura di riferimento nelle associazioni per le malattie rare. L'episodio mette in evidenza l'impatto devastante della sindrome di Netherton, una rara malattia della pelle caratterizzata da dolore intenso, riacutizzazioni croniche e frequenti ricoveri.
Mandy, che ricopre il ruolo di Responsabile medico e delle comunicazioni dell'Ichthyosis Support Group nel Regno Unito e la presidenza del European Network for Ichthyosis, racconta la sua esperienza personale con la patologia. La pubblicazione coincide con il progresso di QRX003, il candidato principale di Quoin per il trattamento della sindrome di Netherton, che ha mostrato risultati promettenti negli studi clinici pivotal in corso.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha publicado el cuarto episodio de su serie de v铆deos NETHERTON NOW, protagonizado por Mandy Aldwin-Easton, destacada defensora de pacientes y l铆der en organizaciones de enfermedades raras. El episodio pone de manifiesto el devastador impacto del s铆ndrome de Netherton, una rara afecci贸n cut谩nea caracterizada por dolor intenso, brotes cr贸nicos y hospitalizaciones frecuentes.
Mandy, que es Directora M茅dica y de Comunicaciones del Ichthyosis Support Group del Reino Unido y presidenta del European Network for Ichthyosis, comparte su experiencia personal con la enfermedad. La publicaci贸n coincide con el avance de QRX003, el principal candidato de Quoin para el tratamiento del s铆ndrome de Netherton, que ha mostrado resultados prometedores en los ensayos cl铆nicos pivotales en curso.
Quoin Pharmaceuticals (NASDAQ: QNRX)臧� NETHERTON NOW 牍勲敂鞓� 鞁滊Μ歃堨潣 雱� 氩堨Ц 鞐愴敿靻岆摐毳� 瓿店皽頄堨姷雼堧嫟. 鞚措矆 鞐愴敿靻岆摐鞐愲姅 頋穩歆堩櫂 鞓鬼樃 雼泊鞐愳劀 頇滊彊頃橂姅 鞝�氇呿暅 頇橃瀽 鞓鬼樃鞛� Mandy Aldwin-Easton臧� 於滌棸頃╇媹雼�. 鞐愴敿靻岆摐電� 鞁暅 韱奠, 毵岇劚 鞎呿檾 氚� 鞛潃 鞛呾洂鞚� 韸轨鞚� 頋穩 頂茧秬 歆堩櫂鞚� 雱ろ劙韸� 歃濏泟甑办澊 齑堧灅頃橂姅 鞁皝頃� 鞓來枼鞚� 臁半獏頃╇媹雼�.
鞓侁淡 旮半皹 Ichthyosis Support Group鞐愳劀 鞚橂 氚� 旎る雼堨紑鞚挫厴 毵る媹鞝�搿� 頇滊彊頃橁碃 鞛堨溂氅� European Network for Ichthyosis鞚� 須岇灔鞚� 毵￡碃 鞛堧姅 Mandy電� 鞛愳嫚鞚� 臧滌澑鞝侅澑 韴硲 瓴巾棙鞚� 瓿奠湢頃╇媹雼�. 鞚措矆 瓿店皽電� 雱ろ劙韸� 歃濏泟甑� 旃橂毳� 鞙勴暅 Quoin鞚� 欤检殧 頉勲炒氍检 QRX003鞚� 臧滊皽 歆勳爠鞐� 毵烄栋 鞚措（鞏挫鞙茧┌, 鞚� 頉勲炒氍检鞚� 歆勴枆 欷戩澑 欤检殧 鞛勳儊鞁滍棙鞐愳劀 鞙犽頃� 瓴瓣臣毳� 氤挫榾鞀惦媹雼�.
Quoin Pharmaceuticals (NASDAQ: QNRX) a publi茅 le quatri猫me 茅pisode de sa s茅rie vid茅o NETHERTON NOW, mettant en vedette Mandy Aldwin-Easton, une militante reconnue pour les patients et une dirigeante d'organisations d茅di茅es aux maladies rares. L'茅pisode souligne l'impact d茅vastateur du syndrome de Netherton, une affection cutan茅e rare caract茅ris茅e par des douleurs intenses, des pouss茅es chroniques et des hospitalisations fr茅quentes.
Mandy, qui est responsable m茅dicale et des communications de l'Ichthyosis Support Group bas茅 au Royaume鈥慤ni et pr茅sidente du European Network for Ichthyosis, partage son parcours personnel avec la maladie. Cette diffusion co茂ncide avec l'avanc茅e de QRX003, le principal candidat-m茅dicament de Quoin pour le traitement du syndrome de Netherton, qui a montr茅 des r茅sultats prometteurs dans les essais cliniques pivots en cours.
Quoin Pharmaceuticals (NASDAQ: QNRX) hat die vierte Folge seiner Videoreihe NETHERTON NOW ver枚ffentlicht, in der Mandy Aldwin-Easton auftritt, eine prominente Patientenvertreterin und F眉hrungspers枚nlichkeit in Organisationen f眉r seltene Erkrankungen. Die Folge beleuchtet die verheerenden Auswirkungen des Netherton-Syndroms, einer seltenen Hauterkrankung, die durch starke Schmerzen, chronische Sch眉be und h盲ufige Krankenhausaufenthalte gekennzeichnet ist.
Mandy, die als Managerin f眉r Medizin und Kommunikation der britischen Ichthyosis Support Group und als Pr盲sidentin des European Network for Ichthyosis t盲tig ist, schildert ihren pers枚nlichen Weg mit der Erkrankung. Die Ver枚ffentlichung f盲llt mit dem Fortschritt von QRX003 zusammen, Quoins f眉hrendem Kandidaten zur Behandlung des Netherton-Syndroms, der in laufenden entscheidenden klinischen Studien vielversprechende Ergebnisse gezeigt hat.
- Company's lead product QRX003 showing encouraging improvements in key clinical outcomes in pivotal trials
- Strategic positioning in the rare disease market with late-stage clinical trials
- Strong advocacy relationships and community engagement through video series
- No approved treatment currently available for Netherton Syndrome
- Clinical trials still ongoing with no guaranteed success
New Episode Highlights the Painful, Often Misunderstood AG真人官方ity of Living with Netherton Syndrome and the Urgent Need for Effective Treatments
ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (鈥淨uoin鈥� or the 鈥淐ompany鈥�), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of the fourth episode in its video series. This installment features Mandy Aldwin-Easton, a Netherton Syndrome patient, and a widely recognized, passionate advocate for people living with rare diseases.
Mandy serves as Medical and Communications Manager and Co-founder of the UK-based Ichthyosis Support Group and is President of the European Network for Ichthyosis. In the video, Mandy shares her personal journey living with Netherton Syndrome, from delayed diagnosis, severe, chronic pain, multiple hospitalizations to the profound long-term impact this disease has had on her life.
鈥淥ne thing we don't talk about is how incredibly painful skin is when it doesn't work properly,鈥� Mandy explains in the video. 鈥淚magine millions of paper cuts all over your body. It鈥檚 just so highly unpredictable. The one thing anybody wants with a rare disease like Netherton Syndrome is hope鈥攖hat better treatments are on the way.鈥�
Mandy鈥檚 story underscores the severe physical and emotional toll of the disease. Despite having a highly supportive family and medical advocacy, she has experienced extreme flare-ups, prolonged hospitalizations, and a lack of targeted treatment options throughout her entire life. As an adult, she continues to navigate the complexities of a disease that many still fail to recognize as life-threatening.
鈥淚 couldn鈥檛 go out because my skin was falling off me. It was so incredibly painful that it was just unbearable to walk,鈥� she recalls. 鈥淓ven with hospital stays and treatments, no one really knew how to care for my skin.鈥�
鈥淢andy has long been a pillar of the ichthyosis and Netherton Syndrome communities,鈥� said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. 鈥淣etherton Syndrome is not just a rare skin disease. It is a relentless and punishing condition marked by excruciating pain, debilitating flare-ups, recurrent infections, and emotional trauma. The toll on patients and their families is immense, not only physically and emotionally but also financially, requiring lifelong care, frequent hospitalizations, and ongoing interventions that place a heavy burden on families and healthcare systems. Beyond her personal resilience, Mandy鈥檚 unwavering advocacy has made her a powerful voice for this underserved and often overlooked population. We are honored to feature her in our NETHERTON NOW series and remain steadfast in our mission to bring awareness and hope to those living with this devastating disease.鈥�
The release of this video comes as Quoin continues to advance its lead product candidate, QRX003, in multiple pivotal clinical trials for the treatment of Netherton Syndrome. Recently reported data from ongoing studies have shown highly encouraging improvements in key clinical outcomes.
鈥淢andy鈥檚 story reflects the extraordinary strength and perseverance of patients who have endured a lifetime of suffering without access to an approved treatment,鈥� said Dr. Michael Myers, Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals. 鈥淎s we advance QRX003 through multiple late-stage pivotal trials, voices like Mandy鈥檚 reinforce the urgency of our mission. Quoin is committed to delivering a meaningful treatment for the severely underserved Netherton Syndrome community and to driving forward research that addresses the significant unmet needs across a broader range of rare skin disorders.鈥�
The full video featuring Mandy Aldwin-Easton is available at: .
About QRX003
QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to perform the function of a specific protein called LEKTI. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier. For more information about Quoin鈥檚 current clinical trials, visit: .
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin鈥檚 innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit聽听辞谤听聽for updates.
Cautionary Note Regarding Forward-Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渉ope,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥渁nticipate,鈥� 鈥渓ook forward,鈥� 鈥渂elieve,鈥� 鈥渕ay,鈥� and 鈥渨ill,鈥� among others. All statements that reflect the Company鈥檚 expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: bringing awareness and hope to those living with Netherton Syndrome, continuing to advance QRX003 through multiple late-stage pivotal trials, delivering a meaningful treatment for the Netherton Syndrome community, driving forward research that addresses the significant unmet needs across a broader range of rare skin disorders and Quoin鈥檚 products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome,聽 Palmoplantar Keratoderma, Scleroderma, , Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company鈥檚 current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company鈥檚 ability to deliver a safe and effective treatment for Netherton Syndrome; the Company鈥檚 ability to pursue its regulatory strategy; the Company鈥檚 ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company鈥檚 ability to complete clinical trials on time and achieve desired results and benefits as expected, the Company experiencing unanticipated or higher than expected clinical trial costs; and other factors discussed in the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
Investor Contact:
PCG Advisory
Jeff Ramson
(646) 863-6341
FAQ
What progress has Quoin Pharmaceuticals (QNRX) made in treating Netherton Syndrome?
Who is featured in Quoin Pharmaceuticals' latest NETHERTON NOW video?
What are the main symptoms of Netherton Syndrome highlighted in QNRX's video series?
Where can investors watch Quoin Pharmaceuticals' latest Netherton Syndrome video?
What is the current status of Quoin Pharmaceuticals' QRX003 clinical trials?
